Overview

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Status:
RECRUITING

Trial end date:
2028-08-31

Target enrollment:

Participant gender:

Summary

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).

Phase:

PHASE1

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborators:

Exelixis
Regeneron Pharmaceuticals

Treatments:

cemiplimab